• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Jounce Therapeutics Inc.

    2/9/24 4:05:34 PM ET
    $JNCE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNCE alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    Jounce Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    481116101

    (CUSIP Number)

     

    James Silverman, One Boston Place, 26th Floor, Boston, MA 02108

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    12/31/2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 481116101 13G Page 2 of 6 Page

     

    1. NAMES OF REPORTING PERSONS
      Opaleye Management Inc.
       
     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    20-5648796

       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
       
      (a) ☐
      (b) ☐
     3. SEC USE ONLY
       
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Massachusetts

    NUMBER OF SHARES
    BENEFICIALLY OWNED
    BY EACH REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
       
      0
    6. SHARED VOTING POWER
       
      0
    7. SOLE DISPOSITIVE POWER
       
      0
    8. SHARED DISPOSITIVE POWER
       
      0

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      0
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
       
      ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      0.00%
    12. TYPE OF REPORTING PERSON (see instructions)
       
      CO

     

     

     

     

    CUSIP No. 481116101 13G Page 3 of 6 Page

     

    Item 1.

     

      (a) Name of Issuer: Jounce Therapeutics, Inc., a Delaware corporation (the “Issuer”)
         
      (b) Address of Issuer’s Principal Executive Offices: 780 Memorial Drive, Cambridge, MA 02139

     

    Item 2.

     

      (a)

    Name of Person Filing: This statement is filed by the entities and persons listed below, who are collectively referred to herein as “Reporting Persons” with respect to the shares of common stock of the Company:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Opaleye, LP (“Opaleye”); Opaleye GP LLC, the general partner of Opaleye, L.P. (“Opaleye GP”); and James Silverman, the manager of Opaleye GP LLC.

         
      (b)

    Address of the Principal Office or, if none, residence

     

    One Boston Place, 26th Floor, Boston, MA 02108

         
      (c) Citizenship
         
       

    Opaleye, L.P. is a Delaware limited partnership. Opaleye GP LLC is a Delaware limited liability company. Mr. Silverman is a United States citizen.

         
      (d) Title of Class of Securities
         
        Common Stock, $0.001 par value per share
         
      (e) CUSIP Number 481116101

     

     

     

     

    CUSIP No. 481116101 13G Page 4 of 6 Page

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned: 0
           
      (b) Percent of class: 0.00%
           
      (c) Number of shares as to which the person has: 0
           
        (i) Sole power to vote or to direct the vote 0
           
        (ii) Shared power to vote or to direct the vote
           
        (iii) Sole power to dispose or to direct the disposition of 0
           
        (iv) Shared power to dispose or to direct the disposition of 0

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Not applicable

     

     

     

     

    CUSIP No. 481116101 13G Page 5 of 6 Page

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable

     

    Item 10. Certification.

     

      (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
         
      (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 481116101 13G Page 6 of 6 Page

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    02/09/2024

    Date

     

    /s/ James Silverman

    Signature

     
    James Silverman
    Managing Member of Opaleye GP LLC , the General Partner of Opaleye, L.P.
    Name/Title

     

     

    Get the next $JNCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JNCE

    DatePrice TargetRatingAnalyst
    5/11/2022$15.00 → $7.00Outperform → Neutral
    Robert W. Baird
    5/6/2022$15.00 → $20.00Outperform → Strong Buy
    Raymond James
    3/16/2022$17.00Outperform
    SMBC Nikko
    2/4/2022Market Perform → Outperform
    Cowen & Co.
    11/5/2021$10.00 → $15.00Outperform
    Raymond James
    9/14/2021$10.00Market Perform → Outperform
    Raymond James
    More analyst ratings

    $JNCE
    Financials

    Live finance-specific insights

    See more
    • Redx and Jounce Announce Recommended Business Combination

      Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include discovery projects from both Redx and Jounce Combined group to be called Redx Inc. listed on Nasdaq under the ticker REDX and led by Redx CEO Lisa Anson with cash runway into H2 2025 ALDERLEY PARK, United Kingdom and CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) today announce an unanimously recommended Business Combination of the

      2/23/23 2:30:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Reports Third Quarter 2022 Financial Results

      - INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress - - SELECT randomized trial of pimivalimab +/- vopratelimab phase 2 data at ESMO-IO Annual Congress - - Two preclinical posters on JTX-1484 and LILRB family at SITC 2022 - - Ended the quarter with $130.3 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the third quart

      11/10/22 7:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022

      CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022. Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m. ET. Conference Call and WebcastTo access the conference call, please register here and please be advised to do so at least 10 minutes prior to joining the call. The live webcast can be accessed under "Events & Presentations" in the Investors and Me

      10/27/22 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Jounce Therapeutics Inc.

      15-12G - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/15/23 7:40:24 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Jounce Therapeutics Inc.

      EFFECT - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/5/23 12:15:08 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Jounce Therapeutics Inc.

      EFFECT - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/5/23 12:15:07 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $JNCE
    Leadership Updates

    Live Leadership Updates

    See more

    $JNCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $JNCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $JNCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 4 filed by Concentra Biosciences, Llc

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:38:21 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Tang Kevin C

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:37:26 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Concentra Biosciences, Llc claimed ownership of 36,367,727 shares

      3 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:35:30 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors

      CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Constellation Pharmaceuticals and former Jounce chief business officer, Jigar Raythatha, to its board of directors. "It's incredibly exciting to welcome Jigar to our board of directors. Not only does Jigar bring over 20 years of biotechnology industry experience, but he also comes with a unique position as an early employee of the company at its inception," said Richard Murray, Ph.D., chief executive offic

      9/15/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Dmitri Wiederschain, Ph.D., as Chief Scientific Officer. "The addition of Dmitri to the Jounce team comes at an exciting juncture in our company development," said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. "Dmitri brings a broad knowledge of contemporary immuno-oncology approaches, tumor immunology and cancer biology. His expertise with preclinical target discovery and first-in-human research will

      4/12/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors

      CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Luisa Salter-Cid, Ph.D., to its board of directors. “We are thrilled to welcome Luisa to our board of directors,” said Perry Karsen, chairman of the board of Jounce Therapeutics. “Luisa brings over 20 years of experience in the healthcare industry, specifically in immunology and immuno-oncology, and we look forward to the unique and valuable perspective that her strategic leadership will bring to Jounce.” Dr. Salter-Cid currently serves a

      2/12/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13G/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/14/24 8:50:07 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Jounce Therapeutics Inc.

      SC 13G - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/9/24 4:05:34 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13G/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/2/24 12:28:25 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Announces Closing of Tender Offer

      CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Concentra Biosciences, LLC ("Concentra"), through its wholly owned subsidiary Concentra Merger Sub, Inc. ("Concentra Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of the common stock of Jounce for $1.85 per share in cash plus a non-tradeable contingent value right (a "CVR") per share. The $1.85 per share upfront consideration represents a premium of approximately

      5/3/23 8:35:17 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce's Board of Directors to withdraw the recommendation for the all-share merger transaction with Redx (the "Redx Business Combination"). Jounce's decision was based upon the receipt of an unsolicited proposal from Concentra Biosciences, LLC ("Conc

      4/3/23 2:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ("Concentra") will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right (the "CVR"). The $1.85 per share upfront con

      3/27/23 9:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Jounce Therapeutics from Outperform to Neutral and set a new price target of $7.00 from $15.00 previously

      5/11/22 6:18:27 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics upgraded by Raymond James with a new price target

      Raymond James upgraded Jounce Therapeutics from Outperform to Strong Buy and set a new price target of $20.00 from $15.00 previously

      5/6/22 7:22:10 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SMBC Nikko initiated coverage on Jounce Therapeutics with a new price target

      SMBC Nikko initiated coverage of Jounce Therapeutics with a rating of Outperform and set a new price target of $17.00

      3/16/22 7:50:25 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care